Juvenile Myasthenia Gravis: A Paediatric Perspective by Finnis, Maria F. & Jayawant, Sandeep
SAGE-Hindawi Access to Research
Autoimmune Diseases
Volume 2011, Article ID 404101, 7 pages
doi:10.4061/2011/404101
Review Article
JuvenileMyastheniaGravis: A Paediatric Perspective
MariaF.FinnisandSandeepJayawant
Department of Paediatric Neurology, Children’s Hospital, John RadcliﬀeH o s p i t a l ,O x f o r dO X 39 D U ,U K
Correspondence should be addressed to Sandeep Jayawant, sandeep.jayawant@orh.nhs.uk
Received 1 June 2011; Accepted 10 August 2011
Academic Editor: Johan A. Aarli
Copyright © 2011 M. F. Finnis and S. Jayawant.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Myasthenia gravis (MG) is an autoimmune disease in which antibodies are directed against the postsynaptic membrane of the
neuromuscular junction, resulting in muscle weakness and fatigability. Juvenile myasthenia gravis (JMG) is a rare condition
of childhood and has many clinical features that are distinct from adult MG. Prepubertal children in particular have a higher
prevalenceofisolatedocularsymptoms,lowerfrequencyofacetylcholinereceptorantibodies,andahigherprobabilityofachieving
remission. Diagnosis in young children can be complicated by the need to diﬀerentiate from congenital myasthenic syndromes,
which do not have an autoimmune basis. Treatment commonly includes anticholinesterases, corticosteroids with or without
steroid-sparing agents, and newer immune modulating agents. Plasma exchange and intravenous immunoglobulin (IVIG) are
eﬀective in preparation for surgery and in treatment of myasthenic crisis. Thymectomy increases remission rates. Diagnosis and
management of children with JMG should take account of their developmental needs, natural history of the condition, and side-
eﬀect proﬁles of treatment options.
1.Introduction
Myasthenia gravis (MG) is an autoimmune disease in which
antibodies are directed at the postsynaptic membrane of
the neuromuscular junction, leading to varying degrees of
muscle weakness and fatigability. Where MG presents before
19yearsofage,itistermedjuvenilemyastheniagravis(JMG).
Although JMG shares many features with the more common
adult MG, there are many important diﬀerences.
In this paper we discuss the pathogenesis, epidemiology,
presentation, treatment, and outcome of JMG and highlight
some of the clinical features and challenges particular to
paediatric patients.
2. Pathogenesis
In the majority of cases MG is caused by antibodies to
the nicotinic acetylcholine receptor (AChR). Antibodies to
the AChR are found in over 80% adults with generalised
disease but only in 55% of adults with weakness conﬁned
to the oculomotor muscles. Patients with AChR antibodies
are often referred to as seropositive. AChR antibodies are
probably less frequent in prepubertal patients than in
adolescent and adult patients [1, 2] (see Table 1). Antibodies
tomuscle-speciﬁckinase(MuSK)andtoLeucinerichprotein
4 (LRP4) have been reported in some seronegative patients.
Childhood myasthenias encompass JMG, which is the
subject of this paper; congenital myasthenic syndromes, a
heterogeneous group of genetically inherited disorders of the
neuromuscular junction [3]; transient neonatal myasthenia,
which results from placental transfer of maternal AChR (or
very occasionally MuSK antibodies) to infants of mothers
with autoimmune MG [4].
3. Epidemiology and ClinicalFeatures
JMG is a rare disorder of childhood, but its incidence and
prevalencevarygeographically.Precisedataonincidenceand
prevalence are not known. Paediatric presentation of MG is
more common in Oriental than in Caucasian populations
[5]. Up to 50% of all cases of MG in Chinese populations
present in childhood, mostly with ocular features, with
a peak age at presentation of 5–10 years [6]. Caucasian
patients, in contrast, are more likely to present in adulthood
[7, 8], with prepubertal onset in less than 10% cases [2, 9].2 Autoimmune Diseases
Table 1: Comparisons of prepubertal and postpubertal features of
JMG.
Prepubertal Pubertal Postpubertal/
adult
Male:female ratio M = FF > M4 . 5:1 F> M4 . 5:1
Patients with AChR
antibodies detected in
generalised disease
50–71%
[1, 2]
68–92%
[1, 2] 80–90%
Ocular presentation
Caucasian 40% [7] 9–16% [12] 28% [6]
Chinese 75% [6]
Progression of OMG
to generalised MG
8–15%
[17, 18]
23–43%
[16, 19] 79% [8]
Remission
(spontaneous or with
treatment)
42–60%
[1, 2, 20] 26% [2] 38% [9]
The most frequent clinical presentation of JMG is with
ptosis, which is often associated with other ocular symp-
toms namely unilateral or asymmetric ophthalmoplegia,
strabismus, and lid twitch, which may only be elicited after
sustained upgaze [10]. These symptoms cause particular
problems in children as, if severe, they may cause persistent
amblyopia [11]. Most children also develop generalised
muscle weakness, which presents as painless fatigability of
the bulbar and limb musculature, with resultant dyspho-
nia, dysphagia, and proximal limb weakness. Weakness is
often ﬂuctuating and usually becomes more pronounced
through the day and improves with rest. Children are at
risk of choking or aspiration and are at increased risk of
chest infection. Occasionally, impairment of the respiratory
muscles necessitates ventilatory support. This is known as
“myasthenic crisis”.
Prepubertal children presenting with JMG have some
interesting and distinct clinical features compared with those
who present around or after puberty [1, 2]. Prepubertal
JMG is more likely to manifest as ocular myasthenia [12].
There is an equal male: female ratio [13], in contrast to
the female predominance that is seen in peri-/postpubertal
children, and a better prognosis, with a higher rate of
spontaneous remission in prepubertal presenters [1, 12].
Peri- or postpubertal patients presenting with JMG share
more similarities with adult-onset MG (see Table 1).
Ocular myasthenia gravis (OMG) is, by deﬁnition, MG
restricted to the oculomotor muscles for 2 years without
becoming generalised [14]. In adult populations up to
80% patients with OMG at presentation will progress to
generalised disease [8, 9, 15]. Case series in children (using
a variety of treatment protocols and follow-up intervals)
have reported lower rates of generalisation than adults
[16]. Progression may be even less frequent in prepubertal
children [17, 18].
3.1. Transient Neonatal Myasthenia. This results from trans-
fer of maternal AChR antibodies across the placenta leading
to defects of neuromuscular transmission in the neonate
[4]. Not all mothers have detectable AChR antibodies and a
few are asymptomatic at the time. Usually the aﬀected baby
is normal at birth, subsequently developing signs such as
hypotonia, weak cry, poor suck, reduced movements, ptosis
and facial weakness, and occasional respiratory insuﬃciency
requiring mechanical ventilation. Short-term treatment with
anticholinesterases is usually suﬃcient.
4.DiagnosisofJMG
JMG is primarily a clinical diagnosis with classical patterns
of ﬂuctuating weakness and fatigability as described above.
A number of diagnostic tools are available to aid with diag-
nosis. In very young children it is particularly important to
distinguishbetweenautoimmunemyastheniaandcongenital
myasthenic syndromes (CMS) as the treatment options,
prognosis, and genetic implications are very diﬀerent (see
Table 2).
CMS usually present in the ﬁrst years of childhood with
variable disability. There is often a positive family history,
and diagnosis is aided primarily by electrophysiology and
DNA analysis and occasionally by muscle biopsy [21]. With
the exception of the autosomal dominantly inherited slow-
channel syndrome, the CMS are inherited by autosomal
recessive mutations, which result in loss of function at the
neuromuscular junction [10].
4.1. Serology. Detection of antibodies to the AChR supports
the diagnosis of JMG. In young children where AChR anti-
bodiesarenegativethiscanleadtodiﬃcultyindiﬀerentiating
from CMS. Some of these children who are negative for
AChR antibodies will have “low aﬃnity” antibodies to the
AChR which were not detectable using the standard assays
[22]. Some children will, in fact, turn out to have CMS.
A variable percentage (0–49%) of MG patients without
AChR antibodies are found to have antibodies against
anotherneuromuscularjunctionprotein,themuscle-speciﬁc
kinase (MuSK) [23]. MuSK positive MG is rare in children,
and these children represent a distinct subgroup of JMG,
with a marked female predominance. MuSK antibodies
appear to be associated with more severe disease with promi-
nent facial and bulbar weakness and frequent respiratory
crises [24].
Patients without antibodies to AChR or MuSK are
describedashavingseronegativemyastheniagravis(SNMG).
SNMG patients are phenotypically more similar to AChR
seropositive patients than MuSK positive patients, both in
clinical presentation and in response to treatment. “Low
aﬃnity” antibodies to clustered AChRs can be found in 60%
of previously deﬁned SNMG patients. These antibodies are
found in all age groups [22].
Seroconversion has been described in a small number of
cases of children who have developed MuSK antibodies after
thymectomy for AChR seropositive MG [25]. This has not
been described in adults.
Other potential antigens at the neuromuscular junction
have been identiﬁed in adults with later-onset MG, butAutoimmune Diseases 3
Table 2: Diﬀerential diagnosis of JMG.
Congenital myasthenic syndromes Usually presents in infancy
but can present later
Mitochondrial cytopathies
Children frequently have
additional neurological
impairments or epilepsy
Myopathies
Including congenital
myopathies and muscular
dystrophies
Neurotoxins For example, botulism,
venoms
Guillain-Barr´ e syndrome
Acute disseminated encephalomyelitis
Multiple sclerosis
Brainstem tumour
Hypothyroidism
the relevance to the childhood population has not been
established [26].
4.2.Pharmacological Investigation. The Tensilon test involves
intravenous infusion of edrophonium, a fast-acting, short-
duration cholinesterase inhibitor. This prevents the break-
down of acetylcholine, thereby increasing the concentration
of the neurotransmitter at the neuromuscular junction. The
patient is observed, and ideally a video recorded, looking for
a transient improvement in previously documented weak-
ness, for example, ptosis, dysphonia. This test is not without
risk and should only be performed by staﬀ experienced in
paediatric resuscitation, due to the cholinergic eﬀects of
edrophonium, which can result in bradycardia, nausea, and
excess salivation.
4.3. Electrophysiology. Electrophysiological testing can be
invaluable in investigation of suspected JMG. Repetitive
nerve stimulation in JMG will show a decrement in the
compound motor action potential of >10% by the 4th or 5th
stimulation.
Single ﬁbre EMG (SFEMG) is especially useful in
diagnosis of seronegative MG and congenital myasthenic
syndromes. It can be technically more diﬃcult in children
due to discomfort of the procedure and the level of cooper-
ation required. It can be done under local or even general
anaesthetic. Sensitivity for a neurotransmission disorder is
97% [27]. A normal result therefore makes a diagnosis of
myasthenia very unlikely [28].
4.4. Imaging. Although thymoma in children is rare, the
thymus must be imaged (usually by CT) once JMG has been
diagnosed. AChR seropositive MG is frequently associated
with changes in the thymus, with histological changes and
in vitro eﬀects suggesting that the thymus plays a pathogenic
role[47].Thymushyperplasiaisthecommonestabnormality
of the thymus in JMG [20]. Thymoma is particularly rare in
prepubertal children [12].
Thymus changes are not a common feature of MuSK
positive disease, and thymoma has not been reported in
MuSK-positive children.
Thymus abnormalities in SNMG patients have been
found to be histologically very similar to the thymus hyper-
plasia seen in AChR seropositive MG [47].
5. Management
Management of children with JMG should be delivered
by a multidisciplinary team comprising a paediatrician
with support from a paediatric neurologist, physiotherapist,
occupational therapist, psychologist, speech therapist and
dietician. Other members of the team may also need to
be involved, depending on associated comorbidities such as
bulbar weakness leading to diﬃculty with oral feeding, or
respiratory insuﬃciency requiring noninvasive ventilatory
support, which should be managed by a respiratory paedi-
atrician.
Treatment of JMG has largely been extrapolated from
adult studies and experience with adult patients. There are
few studies looking speciﬁcally at interventions in children,
particularly prepubertal children (see Table 3). Some case
series include paediatric patients but they are often not
subdivided into prepubertal and postpubertal age groups
for analysis. Given the evidence that prepubertal JMG may
behave quite diﬀerently in terms of disease severity and
progression, this may impact on necessity for treatment and
treatment response. Side-eﬀect proﬁles and considerations
are not always directly comparable between adult and
paediatric populations.
5.1. Acetylcholinesterase Inhibitors. Acetylcholinesterase in-
hibitors are ﬁrst-line treatment in JMG and provide symp-
tomatic relief. In mild cases and in some cases of ocular
MG, acetylcholinesterase therapy may be suﬃcient. Pyri-
dostigmine is a long-acting cholinesterase inhibitor that is
commonly used. Dosing is usually 4–6 times per day and is
tailored to eﬀects. Cautious use in MuSK-positive children is
advised due to risk of acetylcholine hypersensitivity [48].
5.2. Thymectomy. Because of the presumed role of the thy-
mus in the pathogenesis of MG, thymectomy is a recognised
aspect of management. Thymectomy may remove thymic
germinal centres and disrupt antibody diversiﬁcation [47].
A systematic review of the literature concluded that thymec-
tomy increases the probability of remission or improve-
ment of symptoms in AChR seropositive, nonthymomatous,
autoimmune MG [49]. This paper included only one pae-
diatric study [31]. More recent reviews of children including
prepubertalpatients,alsosuggestedincreasedremissionrates
after thymectomy [30, 32]. Caution needs to be taken in
early childhood due to subsequent immunosuppression and
the high rates of spontaneous remission in prepubertal
presenters.
Current evidence suggests that thymectomy should not
be recommended in MuSK-positive disease as it is unclear
whether it confers any beneﬁt [29, 50, 51].4 Autoimmune Diseases
Table 3: Treatment options in JMG.
Treatment Evidence of eﬃcacy in generalised JMG Reference
Acetylcholinesterase
inhibitors
First line therapy.May be suﬃcient in ocular JMG
or mild generalised JMG Skeie et al., 2010 [29]
Thymectomy
Recommended to increase remission rates in
postpubertal, seropositive children. Not
recommended in prepubertal children
Hennessey et al., 2011 [30]
Rodriguez et al., 1983 [31]
Tracy et al., 2009 [32]
Lindner et al., 1997 [20]
Steroids
Often used in combination with steroid sparing
agents. Signiﬁcant side-eﬀect proﬁle if used
long-term at high dose
Schneider-Gold et al., 2005 Cochrane review: one
JMG study, others adult or unspeciﬁed age ranges
[33]
Zhang et al., 1998 [6]
Steroid sparing agents
Azathioprine Usually used in combination with corticosteroids.
Occasionally used alone.
Mertens et al., 1981 [34] includes some children
but no subgroup analysis
Gold et al., 2008 [35]
Palace et al., 1998 [36] adult study
Cyclosporin A As monotherapy or in conjunction with
corticosteroids
Tindall et al., 1987 [37] adult study
Hart et al., 2009 (Cochrane) [38] series include
some children
Cyclophosphamide
De Feo et al., 2002 [39] adult population
Hart et al., 2009 [38] (Cochrane) series include
some children
Tacrolimus
Furukawa et al., 2008 [40]
Ponseti et al., 2008 [41]
both include post pubertal children
Ishigaki et al., 2009 [42] prepubertal female
MMF Hehir et al., 2010 [43] includes some
peri-/postpubertal children
Rituximab Wylam et al., 2003 [44] pediatric case
IVIG/Plasma exchange Selcen et al., 2000 [45]
Gajados et al., 2008, Cochrane database [46]
Thymectomy in pure OMG remains controversial.
Whereas OMG is not life threatening, patients may be
dependent on long-term immunosuppressant medications,
including corticosteroids, with the resultant side eﬀects
which can be substantial in children. Persistent amblyopia
can result in children as the visual system is maturing. As
discussed above, we know that a proportion of children will
progresstogeneraliseddisease.Thymectomyisnotprovento
reduce risk of progression of OMG to generalised JMG [52]
and is not routinely indicated in pure OMG in children but
has been performed in refractory cases.
A variety of surgical methods for thymectomy have
been described: full or partial sternotomy, thorascopic, or
transcervical approaches. Evidence suggests that symptom
resolution is equivalent regardless of surgical approach [53,
54]. After thymectomy there is increased risk of antimus-
carinic side eﬀects of cholinesterase inhibitors, and they
should therefore be used under close supervision in the
postoperative period.
5.3. Immunosuppressive Therapies. Frequently some form
of immunosuppression or immunomodulation is required
to improve symptoms of JMG. Corticosteroids are often
eﬀective and are the mainstay of therapy but can worsen
symptoms in the ﬁrst few weeks of use, particularly if started
at high doses [33]. Because of the numerous adverse eﬀects
associated with long-term high-dose steroids, steroids are
often used in combination with a steroid-sparing immuno-
suppressant, for example, azathioprine. Children are at par-
ticular risk of steroid side eﬀects, including growth failure,
susceptibility to severe infection, and delay in receiving live
vaccinations.
Azathioprine is a purine analogue that suppresses B and
T cell proliferation. It has been found to be eﬀective when
used alone [34], but is most commonly used in combination
with prednisolone as a steroid-sparing agent. Beneﬁcial
eﬀects may take months to be seen [35] but eventually result
in weaning of steroid doses [36].
Some studies have suggested that azathioprine or corti-
costeroids may reduce the likelihood of progression of OMG
to the generalised form of disease [55, 56]. Although these
studiesincludedsomechildrenintheircaseseries,thesewere
not speciﬁcally paediatric studies, and given the lower rates
of progression in prepubertal children anyway, these ﬁndings
are of uncertain relevance in paediatric practice.
Patients unresponsive or intolerant to azathioprine
should be considered for other immunosuppressive agents,
which could include cyclosporin A (which has a fasterAutoimmune Diseases 5
time to symptomatic beneﬁt than azathioprine [37]) or
cyclophosphamide [39]. A Cochrane review suggests that
cyclosporin either as monotherapy or with corticosteroids,
or cyclophosphamide in conjunction with corticosteroids,
improves symptoms of MG within 1 year [38].
Mycophenolate mofetil (MMF) blocks purine synthesis
by selectively inhibiting proliferation of activated T and B
lymphocytes [57]. A recent retrospective study of AChR
seropositive patients, which included children (age range
11–87y), concluded some beneﬁt of MMF when used
either as monotherapy or in conjunction with prednisolone.
Maximum eﬀects may not be seen until after one year of
treatment [43].
Tacrolimus inhibits interleukin 2. Eﬃcacy studies have
been carried out in adults and postpubertal children and
have shown early and sustained improvement of symptoms
with tacrolimus, allowing dose reduction of prednisolone
and in many cases its complete withdrawal. These steroid
sparing eﬀects were seen within 6 months [40, 41]. A case
has also been reported of tacrolimus being successfully used
as adjunctive therapy in refractory pure ocular myasthenia in
a3 - y e a r - o l dg i r l[ 42].
Rituximab is a chimeric IgG monoclonal antibody that
depletes B cells and has been used in refractory JMG [44].
5.4. Plasma Exchange/Intravenous Immunoglobulin (IVIG).
Improvement in symptoms after plasma exchange or admin-
istration of IVIG is usually temporary, 4–10 weeks. Their use
isthereforelargelyreservedtooptimise conditionforsurgery
before thymectomy and in management of myasthenic crisis
[45, 46, 58]. A single randomised controlled trial showed no
evidence for superior beneﬁt of plasma exchange over IVIG
in treatment of myasthenic crisis [59].
Eﬃcacystudiesarenotavailableforprepubertalchildren.
Allogeneic hematopoietic cell transplantation has been
reported as successful in treating a 17-year-old male with
refractory JMG that had been diagnosed aged 11 months
[60].
6. Outcome
Outcomes in JMG have improved signiﬁcantly over the last
decade,withbetterrecognition,diagnosis,andmoreeﬀective
therapies, and long-term prognosis is good [61]. Children
with JMG exhibit higher rates of remission than adults. This
includes spontaneous remission and remission following a
periodofdrugtherapy.Prepubertalchildrenhavethehighest
rates of spontaneous remission. Remission rates also appear
to be inﬂuenced by ethnic origin [1].
7. Summary
JMG is a rare, autoimmune condition of childhood that
shares many characteristics of clinical presentation and
management strategies with the adult form of the disease.
However, as described in this paper, there are many impor-
tant aspects that are speciﬁc to the paediatric population,
in particular the distinct clinical features of the prepubertal
presentations, diﬀerences in rates of AChR seropositivity,
diagnostic challenges including diﬀerentiation from CMS,
and response to therapy. Further studies looking at eﬃcacy
of therapies in pre- and postpubertal children are needed
to better understand and support this distinct group of
patients.
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